Difficulties in conducting large-scale studies on rare diseases: the case for pediatric hepatitis C infection.
Süoglu
Ozlem Durmaz
OD
D000998:Antiviral Agents / Q000627:therapeutic use*; D002648:Child; D004359:Drug Therapy, Combination; D005838:Genotype; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D018401:Sample Size; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin